secwatch.observer — SEC 8-K summary
======================================

Issuer:     Savara Inc (SVRA)
CIK:        0001160308
Form:       8-K
Filed at:   2025-10-29T23:59:59+00:00
Accession:  0001193125-25-256290
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Savara secures $75M royalty funding from RTW for MOLBREEVI; also discloses securities class action
--------------------------------------------------------------------------------

- RTW commits $75M upon FDA approval of MOLBREEVI for autoimmune PAP; funds to support U.S. launch and repay debt.
- Royalty rates tiered from 7.0% to 1.0% of U.S. net sales; 7.0% tier rises to 9.5% if prior-year sales fall short.
- Royalty capped at $187.5M; company expects effective rate in low-single digits over life of agreement.
- Securities class action filed Sept 8, 2025 alleging misstatements about MOLBREEVI regulatory filings; company intends to defend.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1160308/000119312525256290/0001193125-25-256290-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1160308/000119312525256290/d55049d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-256290

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer